Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

Cancer02:18

Cancer

51.6K
Cancers arise due to mutations in genes involved in the regulation of cell division, which leads to unrestricted cell proliferation. Modern science and medicine have made great strides in the understanding and treatment of cancer, including eradicating cancer in some patients. However, there is still no cure for cancer. This is largely due to the fact that cancer is a large group of many diseases.
51.6K
Cancers Originate from Somatic Mutations in a Single Cell02:21

Cancers Originate from Somatic Mutations in a Single Cell

12.5K
Cancer arises from mutations in the critical genes that allow healthy cells to escape cell cycle regulation and acquire the ability to proliferate indefinitely. Though originating from a single mutation event in one of the originator cells, cancer progresses when the mutant cell lines continue to gain more and more mutations, and finally, become malignant. For example, chronic myelogenous leukemia (CML) develops initially as a non-lethal increase in white blood cells, which progressively...
12.5K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

3.6K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
3.6K
Pigmentation01:19

Pigmentation

3.8K
The color of the skin is influenced by a number of pigments, including melanin, carotene, and hemoglobin. Recall that melanin is produced by cells called melanocytes, which are found scattered throughout the stratum basale of the epidermis. The melanin is transferred to the keratinocytes via melanosomes.
Melanin occurs in two primary forms: eumelanin that provides black and brown pigment and pheomelanin that provides red color. Dark-skinned individuals produce more melanin than those with pale...
3.8K
Skin Cancer01:30

Skin Cancer

5.2K
Skin cancer is a type of cancer that occurs when there is an abnormal growth of skin cells, usually triggered by damage to the DNA within the skin cells. It is primarily caused by exposure to ultraviolet (UV) radiation from the sun or artificial sources like tanning beds. Skin cancer is the most common type of cancer worldwide, and its incidence continues to rise.
Basal Cell Carcinoma (BCC): BCC is the most common type of skin cancer, accounting for about 80% of cases. It typically develops in...
5.2K
Tumor Immunotherapy01:27

Tumor Immunotherapy

2.5K
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
2.5K

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

Past, Present and Future: The Role of Sentinel Lymph Node Biopsy (SLNB) for Merkel Cell Carcinoma.

ANZ journal of surgery·2026
Same author

Standard neoadjuvant immunotherapy in patients with resectable stage III Melanoma - The early Australian experience.

European journal of cancer (Oxford, England : 1990)·2026
Same author

European consensus-based interdisciplinary guideline for invasive cutaneous squamous cell carcinoma: Part 2. Treatment - update 2026.

European journal of cancer (Oxford, England : 1990)·2026
Same author

European consensus-based interdisciplinary guideline for invasive cutaneous squamous cell carcinoma. Part 1: Diagnostics and prevention - Update 2026.

European journal of cancer (Oxford, England : 1990)·2026
Same author

On the survival benefit from sentinel node biopsy for melanoma.

The Lancet. Oncology·2026
Same author

Optimal Follow-Up of Sentinel Node Positive Melanoma Patients?

Annals of surgical oncology·2026
Same journal

Inherited retinal degenerations: clinical phenotypes and emerging therapies.

Lancet (London, England)·2026
Same journal

Documenting hospice care.

Lancet (London, England)·2026
Same journal

After the wood chipper.

Lancet (London, England)·2026
Same journal

Assisted dying and the silencing of medicine's next generation.

Lancet (London, England)·2026
Same journal

Linguistic pragmatism: a woman with progressive abdominal pain in Thailand.

Lancet (London, England)·2026
Same journal

Medical compartmentalisation: a patient with chromosome 22q11.2 deletion syndrome in Japan.

Lancet (London, England)·2026
查看所有相关文章

相关实验视频

Updated: Apr 29, 2026

Isolated Hepatic Perfusion as a Treatment for Liver Metastases of Uveal Melanoma
09:52

Isolated Hepatic Perfusion as a Treatment for Liver Metastases of Uveal Melanoma

Published on: January 25, 2015

13.9K

黑色素瘤

Dirk Schadendorf1, Alexander C J van Akkooi2, Carola Berking3

  • 1Department of Dermatology, University Hospital Essen, Essen, Germany; German Cancer Consortium, Heidelberg, Germany.

Lancet (London, England)
|September 22, 2018
PubMed
概括
此摘要是机器生成的。

由于向治疗和免疫治疗,先进的黑色素瘤治疗得到了显著改善. 这些创新为长期控制和治疗晚期皮肤黑色素瘤提供了新的希望.

更多相关视频

A Melanoma Patient-Derived Xenograft Model
07:07

A Melanoma Patient-Derived Xenograft Model

Published on: May 20, 2019

13.2K
A Robust Discovery Platform for the Identification of Novel Mediators of Melanoma Metastasis
07:41

A Robust Discovery Platform for the Identification of Novel Mediators of Melanoma Metastasis

Published on: March 8, 2022

2.9K

相关实验视频

Last Updated: Apr 29, 2026

Isolated Hepatic Perfusion as a Treatment for Liver Metastases of Uveal Melanoma
09:52

Isolated Hepatic Perfusion as a Treatment for Liver Metastases of Uveal Melanoma

Published on: January 25, 2015

13.9K
A Melanoma Patient-Derived Xenograft Model
07:07

A Melanoma Patient-Derived Xenograft Model

Published on: May 20, 2019

13.2K
A Robust Discovery Platform for the Identification of Novel Mediators of Melanoma Metastasis
07:41

A Robust Discovery Platform for the Identification of Novel Mediators of Melanoma Metastasis

Published on: March 8, 2022

2.9K

科学领域:

  • 癌症学
  • 皮肤病学
  • 癌症研究

背景情况:

  • 皮肤黑色素瘤是全球严重的健康问题,每年造成大量死亡.
  • 几十年来,晚期黑色素瘤的治疗选择有限,临床试验历史上没有成功.
  • 生物理解和治疗的近期进展彻底改变了黑色素瘤的治疗方法.

研究的目的:

  • 审查治疗晚期皮肤黑色素瘤的变革性进展.
  • 突出新型治疗药物和策略的影响.

主要方法:

  • 对晚期黑色素瘤的最新临床试验和生物研究进行了回顾.
  • 针对性治疗的分析,包括BRAF抑制剂和MEK抑制剂.
  • 对免疫疗法的评估,特别是对抗PD-1抗体等检查点调节剂.

主要成果:

  • 针对性治疗 (BRAF/ MEK 抑制剂) 显著改善了 BRAF V600 突变患者的反应率和整体存活率.
  • 检查点抑制剂 (抗PD-1) 在局部疾病中表现出临床成功,延长了无复发和整体存活时间.
  • 晚期黑色素瘤是开发固体癌症新疗法的典范.

结论:

  • 创新治疗已经将晚期黑色素瘤转变为可控的疾病,
  • 针对性药物和免疫疗法为长期瘤控制和潜在的治愈提供了希望.
  • 在晚期黑色素瘤的持续研究有助于更广泛的瘤进展.